Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Summarize this article with:
SA Transcripts157.31K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma December 11, 2025 9:00 AM EST Company Participants Phillip L'Huillier - CEO & DirectorNermeen Varawalla - Chief Medical OfficerMary-Ann Chang Conference Call Participants Julie Simmonds - Panmure Liberum Limited, Research DivisionMichael Mitchell - Cavendish Securities plc, Research DivisionEdward Sham - Singer Capital Markets Securities Limited, Research DivisionEdward Brounger Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the continued improvement in PFS with iSCIB1+ in advanced melanoma Phase II update, ESMO IO. [Operator Instructions] I would like to remind all participants that this call is being recorded. I will now hand over to Phil L'Huillier, Chief Executive Officer, to open the presentation. Please go ahead. Phillip L'HuillierCEO & Director Thank you. Good afternoon. Good morning, everyone. Thank you for joining us today. Today, I'm excited to share with you an update on the SCOPE data. And we're calling this presentation redefining the standard of care of advanced melanoma. Because of the data that we're seeing from the SCOPE study, we believe we are starting to see that we could really redefine the standard of care. Today, for this presentation, I'm joined by the Chief Medical Officer of the company, Nermeen Varawalla, and she will walk you through the data shortly. Here's our forward-looking statement for reference. And let me start off and summarize some key highlights in the presentation today. Firstly, we have -- we're seeing a very strong progression-free survival signal or iSCIB1+ with the checkpoint blockade combination. And the data is, in fact, demonstrating a 74% PFS at 16 months. That's a significant delta over standard of care and over historic controls. And we're seeing a strong progression-free survival data that is also showing through in populations that typically have had a poor prognosis to checkpoint blockade, and Nermeen will Recommended For You